ReviewNature reviews. Urology2015
Risk-adapted strategy for the kidney-sparing management of upper tract tumours.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.World journal of urology · 2024Pooled it
- A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2016Pooled it
- When disease travels downstream: The effect of intravesical recurrences in patients treated for upper tract urothelial carcinoma.BJUI compass · 2026Article
- Conservative Management of Upper Tract Urothelial Carcinoma: A Narrative Review.Journal of clinical medicine · 2026Review
- Development of a preoperative risk prediction model of muscle-invasive upper tract urothelial carcinoma using clinical and radiomic computed tomography features Initial results from a multi-institutional, Canadian study.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Preoperative CT-based radiomics model for predicting muscle invasion in patients with upper tract urothelial carcinoma below T3 stage.Abdominal radiology (New York) · 2025Article
- Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study.Investigative and clinical urology · 2025Article
- The Recurrence Rates at Three Years for the Conservatively Managed UTUC Cases Using NBI-Assisted Flexible Ureteroscopy and Holmium Laser Vaporization.Medicina (Kaunas, Lithuania) · 2024Article
- Urothelial cancer: state of art in Ukraine and improvement pathways.Annals of medicine and surgery (2012) · 2024Article
- Impact of surgical management of upper tract urothelial cancer in octogenarians: A population-based study.Current urology · 2024Article
- Upper Tract Urothelial Cancer: Guideline of Guidelines.Cancers · 2024Review
- Management of Upper Tract Urothelial Carcinoma in a Double Collecting System Kidney.Journal of personalized medicine · 2024Review
- Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma.Cancers · 2023Review
- Adjuvant intraluminal therapies for upper tract urothelial carcinoma.Translational andrology and urology · 2023Review
- [Urothelial carcinoma of the upper urinary tract].Urologie (Heidelberg, Germany) · 2023Article
- Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies.European urology open science · 2023Review
- Article
- Case Report: Step-by-step procedures for total intracorporeal laparoscopic kidney autotransplantation in a patient with distal high-risk upper tract urothelial carcinoma.Frontiers in oncology · 2023Article
- The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence.Bladder cancer (Amsterdam, Netherlands) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conservative management of upper tract urothelial carcinoma (UTUC) was traditionally restricted to patients with imperative indications only. However, current recommendations suggest selected patients with normal, functioning contralateral kidneys should also be considered for such an approach. A risk-adapted strategy to accurately select patients who could benefit from kidney-sparing surgery without compromising their oncological safety has been advocated. A number of kidney-sparing surgical procedures are available. Despite the advent of ureteroscopic management, segmental ureterectomy and the percutaneous approach both have specific indications for use that predominantly depend on the tumour location and progression risk. These kidney-sparing procedures are cost-effective, and when used to treat patients with low-risk UTUC, are associated with oncological outcomes similar to radical nephroureterectomy. Systematic second-look endoscopy combined with upper tract instillations of topical chemotherapeutic agents after ureteroscopic or percutaneous surgery and a single early intravesical instillation of mitomycin C after any kidney-sparing procedure might decrease the risks of local recurrence and progression. Meticulous and stringent endoscopic monitoring of the upper and lower urinary tract is a key component of the conservative management of UTUC. Local recurrences are often suitable for repeat conservative therapy, whereas disease progression should be treated with delayed radical nephroureterectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.